Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Maraviroc

FDA-approved product (tablet, oral), marketed as Maraviroc, Selzentry.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Maraviroc
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
CCR5 Co-receptor Antagonist FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Maraviroc in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Maraviroc with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

    NCT06974084 · start 2026-07-15

    Registered record
    Registry ID
    NCT06974084
    Conditions
    Long COVID
    Interventions
    Maraviroc (MVC); Atorvastatin, 10mg, 20mg, 40mg; Placebo, Maraviroc; Placebo, Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-07-15
    Completion
    2027-05
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong COVID
    InterventionMaraviroc (MVC); Atorvastatin, 10mg, 20mg, 40mg; Placebo, Maraviroc; Placebo, Atorvastatin
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

    NCT03163277 · start 2017-05-15

    Registered record
    Registry ID
    NCT03163277
    Conditions
    Hiv; Neurocognitive Dysfunction
    Interventions
    emtricitabine, darunavir/cobicistat, maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-05-15
    Completion
    2020-06-30
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv; Neurocognitive Dysfunction
    Interventionemtricitabine, darunavir/cobicistat, maraviroc
    PhasePhase 4
    Registry statusTerminated

  • Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

    NCT04721301 · start 2017-01-15

    Registered record
    Registry ID
    NCT04721301
    Conditions
    Colorectal Cancer Metastatic; Pancreatic Cancer Metastatic
    Interventions
    Nivolumab plus Ipilimumab plus Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-01-15
    Completion
    2023-03-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic; Pancreatic Cancer Metastatic
    InterventionNivolumab plus Ipilimumab plus Maraviroc
    PhasePhase 1
    Registry statusCompleted

  • Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

    NCT02858401 · start 2015-01-29

    Registered record
    Registry ID
    NCT02858401
    Conditions
    HIV-1 Infection
    Interventions
    Vesatolimod; Placebo; ARV regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01-29
    Completion
    2019-02-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionVesatolimod; Placebo; ARV regimen
    PhasePhase 1
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

    NCT03178084 · start 2014-10-15

    Registered record
    Registry ID
    NCT03178084
    Conditions
    HIV/AIDS
    Interventions
    Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID; Efavirenz QD + Zidovudine/Lamivudine BID; Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-15
    Completion
    2017-03-07
    Enrolment
    721

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionMaraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID; Efavirenz QD + Zidovudine/Lamivudine BID; Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
    PhasePhase 3
    Registry statusCompleted

  • Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

    NCT02799888 · start 2014-04

    Registered record
    Registry ID
    NCT02799888
    Conditions
    Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation
    Interventions
    Maraviroc; Cyclosporine (in HLA-Unrelated Donor Transplantation); Tacrolimus (in HLA-Mismatched Related Donor Transplantation); Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-04
    Completion
    2017-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-versus-host Disease; Hematopoietic Stem Cell Transplantation
    InterventionMaraviroc; Cyclosporine (in HLA-Unrelated Donor Transplantation); Tacrolimus (in HLA-Mismatched Related Donor Transplantation); Methotrexate
    PhasePhase 2
    Registry statusUnknown

  • Switch to Maraviroc + Integrase Inhibitor

    NCT01896921 · start 2013-09

    Registered record
    Registry ID
    NCT01896921
    Conditions
    HIV
    Interventions
    Switch to Maraviroc + Raltegravir or Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09
    Completion
    2018-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionSwitch to Maraviroc + Raltegravir or Dolutegravir
    PhasePhase 3
    Registry statusCompleted

  • Phase II Maraviroc for GVHD Prevention

    NCT01785810 · start 2013-02

    Registered record
    Registry ID
    NCT01785810
    Conditions
    Hematologic Malignancy
    Interventions
    Maraviroc 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2018-07-12
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy
    InterventionMaraviroc 300 mg
    PhasePhase 2
    Registry statusCompleted

  • Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

    NCT01367236 · start 2013-01

    Registered record
    Registry ID
    NCT01367236
    Conditions
    HIV; Impaired Cognition
    Interventions
    standard care; novel treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-01
    Completion
    2015-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Impaired Cognition
    Interventionstandard care; novel treatment
    PhasePhase 4
    Registry statusCompleted

  • Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

    NCT01980329 · start 2013-01

    Registered record
    Registry ID
    NCT01980329
    Conditions
    Cytochrome P450 CYP3A5 Enzyme Polymorphism; Healthy Subjects; Pharmacokinetics of Maraviroc
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytochrome P450 CYP3A5 Enzyme Polymorphism; Healthy Subjects; Pharmacokinetics of Maraviroc
    InterventionMaraviroc
    PhasePhase 1
    Registry statusCompleted

  • Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

    NCT01749566 · start 2012-12

    Registered record
    Registry ID
    NCT01749566
    Conditions
    HIV
    Interventions
    maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2015-05
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionmaraviroc
    PhasePhase 1
    Registry statusCompleted

  • CCR5-blockade in Metastatic Colorectal Cancer

    NCT01736813 · start 2012-11

    Registered record
    Registry ID
    NCT01736813
    Conditions
    Colorectal Cancer; Neoplasm Metastasis; Liver Metastases
    Interventions
    Maraviroc
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Neoplasm Metastasis; Liver Metastases
    InterventionMaraviroc
    PhaseNot recorded
    Registry statusCompleted

  • First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

    NCT01719627 · start 2012-10

    Registered record
    Registry ID
    NCT01719627
    Conditions
    HIV
    Interventions
    Maraviroc; TVD 300/200 QD; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2015-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMaraviroc; TVD 300/200 QD; Maraviroc
    PhasePhase 1
    Registry statusCompleted

  • Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

    NCT01597895 · start 2012-07

    Registered record
    Registry ID
    NCT01597895
    Conditions
    Healthy
    Interventions
    Maraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    PhasePhase 1
    Registry statusCompleted